A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Schizophrenia

In brief

To assess if PF-04958242 can attenuate the ketamine-induced cognitive impairment in verbal learning and memory, episodic memory and spatial working memory in healthy volunteers.

Key facts

Study ID

NCT01749098

Run by

Biogen

People needed

29

Starts

2012-12-01

Expected to finish

2014-02-01

Last updated by the study team

2019-11-21

Who can join

Age: 21 and older, up to 45. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Healthy male subjects 21 - 45 years old.
• Able to read and write English as primary language.
• Subjects who are willing to comply with study procedures.

You may not qualify if…

• History of any substance abuse or dependence disorder meeting DSM-IV criteria and/or by SCID-NP within the past 12 months, with the exception of nicotine.
• Known sensitivity to ketamine
• Any history of DSM-IV Axis I psychiatric disorders, determined by SCID-NP interview or diagnoses in the view of the investigator.

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — West Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.